Keyword: Serum Institute of India
The chairman of Zhifei Biological Products, which holds Chinese rights to Gardasil and Gardasil 9, boasted a net worth of about $4.6 billion Wednesday.
Serum Institute of India plans to launch four vaccines in the coming years for pneumococcal, HPV, meningococcal and dengue.
Amgen inked a biosim deal with Simcere, Gilead won a Chinese nod for Sovaldi, and Shanghai Pharma is in talks to buy part of Alvogen.
Serum Institute of India has new results from a phase 3 trial of its rotavirus vaccine as it preps to deliver millions of doses.
MSF's strong opposition didn't stop India's government from granting Pfizer a patent that protects Prevnar's exclusivity till 2026.
Takeda has been eyeing India’s vaccine market since at least 2015, and the idea has come to fruition in the form of two licensing deals.
Samsung won FDA nod for a Remicade biosim, Otsuka expanded anemia deal with Akebia, analysts are cautiously optimistic about China's foreign drug proposal.
Serum Institute of India CEO Adar Poonawalla struck a deal on Tuesday to pick up a defunct Czech outfit for €72 million.
WuXi AppTec started IPO prep for core drug R&D, Purdue and Shionogi won approval for a new constipation med, and an Indian CRO's meds were halted by EMA.
A rotavirus vaccine candidate showed better efficacy than Merck’s and GlaxoSmithKline’s approved vaccines in a late-stage trial.